article thumbnail

Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments

Digital Health Global

About Automera Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation. Since our inception in 2022, ClavystBio has committed over US$220m to biotech, diagnostics, and digital health companies, as well as early-stage VC funds.